Assessing clinical progression measures in Alzheimer's disease trials: A systematic review and meta-analysis.

ABSTRACT:

Introduction

Assessing treatments for Alzheimer's disease (AD) relies on reliable tools for measuring AD progression. In this analysis, we evaluate the sensitivity of clinical progression measures in AD within randomized controlled trials (RCTs) with confirmed positive amyloid (Aβ+) status prior to trial enrollment.

Methods

Excluding trials targeting non-cognitive symptoms, we conducted meta-analyses on progression measures from 25 selected RCTs using R version 4.2.0, along with the metafor and emmeans libraries.

Results

The Functional Activities Questionnaire (FAQ) demonstrated the greatest sensitivity over 12 weeks. Other cognitive measures demonstrated lower sensitivity. The integrated Alzheimer's Disease Rating Scale (iADRS) and Clinical Dementia Rating-Sum of Box

SUBMITTER: McLaughlin J 

PROVIDER: S-EPMC11667530 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature